| BÚTOVÁ, Romana, Petra VYCHYTILOVÁ, Jana GREGOROVÁ, Lenka RADOVÁ, Martina ALMASI, Renata BEZDEKOVA, Lucie BROŽOVÁ, Jiří JARKOVSKÝ, Zdenka KNECHTOVA, Martin ŠTORK, Luděk POUR and Sabina ŠEVČÍKOVÁ. LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. Biomedicines. Basel: MDPI, 2021, vol. 9, No 11, p. 1-11. ISSN 2227-9059. Available from: https://dx.doi.org/10.3390/biomedicines9111637. |
Other formats:
BibTeX
LaTeX
RIS
@article{1818659,
author = {Bútová, Romana and Vychytilová, Petra and Gregorová, Jana and Radová, Lenka and Almasi, Martina and Bezdekova, Renata and Brožová, Lucie and Jarkovský, Jiří and Knechtova, Zdenka and Štork, Martin and Pour, Luděk and Ševčíková, Sabina},
article_location = {Basel},
article_number = {11},
doi = {http://dx.doi.org/10.3390/biomedicines9111637},
keywords = {multiple myeloma; plasma cell leukemia; long non-coding RNA; next-generation sequencing; biomarkers; disease progression},
language = {eng},
issn = {2227-9059},
journal = {Biomedicines},
title = {LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients},
url = {https://www.mdpi.com/2227-9059/9/11/1637},
volume = {9},
year = {2021}
}
TY - JOUR
ID - 1818659
AU - Bútová, Romana - Vychytilová, Petra - Gregorová, Jana - Radová, Lenka - Almasi, Martina - Bezdekova, Renata - Brožová, Lucie - Jarkovský, Jiří - Knechtova, Zdenka - Štork, Martin - Pour, Luděk - Ševčíková, Sabina
PY - 2021
TI - LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
JF - Biomedicines
VL - 9
IS - 11
SP - 1-11
EP - 1-11
PB - MDPI
SN - 22279059
KW - multiple myeloma
KW - plasma cell leukemia
KW - long non-coding RNA
KW - next-generation sequencing
KW - biomarkers
KW - disease progression
UR - https://www.mdpi.com/2227-9059/9/11/1637
N2 - Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (p < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression.
ER -
BÚTOVÁ, Romana, Petra VYCHYTILOVÁ, Jana GREGOROVÁ, Lenka RADOVÁ, Martina ALMASI, Renata BEZDEKOVA, Lucie BROŽOVÁ, Jiří JARKOVSKÝ, Zdenka KNECHTOVA, Martin ŠTORK, Luděk POUR and Sabina ŠEVČÍKOVÁ. LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. \textit{Biomedicines}. Basel: MDPI, 2021, vol.~9, No~11, p.~1-11. ISSN~2227-9059. Available from: https://dx.doi.org/10.3390/biomedicines9111637.
|
